P235 Glucocorticoid dose is progressively reduced in Patients with rheumatoid arthritis (RA) receiving sarilumab: results from the open label EXTEND study
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa111.229
Abstract: This post hoc analysis assessed changes in oral glucocorticoid (OGC) use over time in patients receiving sarilumab 200 mg (dose reduction to 150 mg for laboratory abnormalities or per investigator’s discretion) every 2 weeks (q2w)… read more here.
Keywords: day; ped day; grants research; research support ... See more keywords
P083 How are beliefs about osteoporosis medicines elicited and addressed in clinical consultations: a video observational study
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.124
Abstract: In shared decision-making conversations, patients with or at risk of osteoporosis and their clinicians collaborate to decide which drug treatments fit best for each person. The Perceptions and Practicalities Approach (PAPA) specifies three core considerations… read more here.
Keywords: grants research; osteoporosis; osteoporosis drugs; support ... See more keywords
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.234
Abstract: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ demonstrated rapid and clinically meaningful improvements in disease activity across the full spectrum of axial spondyloarthritis (axSpA; active non-radiographic… read more here.
Keywords: ucb pharma; grants research; pharma; axspa ... See more keywords